Review
Copyright ©2013 Baishideng Publishing Group Co.
World J Hepatol. Oct 27, 2013; 5(10): 521-527
Published online Oct 27, 2013. doi: 10.4254/wjh.v5.i10.521
Table 2 Features of the studies on cirrhotic patients
Type studyFollow-up (mo)IFN (wk)Sample sizeMean age (yr)RRRef.
RCT24-866 MU tiw (12-24)T 45/C4555-0.4[31]
NRCT/P12-713 MU tiw (52)T193/C9157-0.1[32]
NRCT/P60-846 MU tiw (26)T82/C81562[33]
NRCT/P433 MU tiw (65)T103/C5957-0.05[34]
RCT606 MU tiw (18) 3 MU tiw (18)T38/C2357> 1[35]
P551 MU tiw (12) 3 MU tiw (12) 6 MU tiw (12) 9 MU tiw (12)T72/C7258-0.2[36]
R963 MU tiw (12)T52/C7156> 1[19]
P606 MU/mo (4) 3 MU/mo (44)T41/C3056-0.1[37]
R963 MU tiw (12)T52/C7156> 1[22]
P603-6 MU tiw plus Ribavirin (2-48)T1057/C56256-0.05[38]
RCT453 MU tiw (48) (post-resection)T76/C7466> 1[39]
P966 MU tiw (24-48)T82/T8157-0.04[40]